Rockwell Medical, Inc. (NASDAQ: RMTI) (the "Company" or "Rockwell Medical") today announced that Charlie Shiner has been appointed Vice President, Marketing, effective immediately. Mr. Shiner will report to Stuart Paul, President & Chief Executive Officer of the Company.

Mr. Shiner joins Rockwell Medical from Otsuka Pharmaceuticals, Ltd., a global pharmaceuticals company focused on the development and marketing of products for the diagnosis and treatment of diseases related to the central nervous system, oncology, gastroenterology, ophthalmology and cardiovascular areas. He most recently served as the marketing franchise leader for Otsuka's renal portfolio, where he successfully launched Otsuka's new therapeutic Jynarque and managed other key renal therapeutics. Previously, he held the roles of Director and Senior Product Manager, Digital Marketing at Otsuka America Pharmaceuticals. In these roles, Mr. Shiner was responsible for the digital marketing of cardio-renal products across applicable professional and consumer channels. Earlier in his career, Mr. Shiner spent 11 years at Pfizer, Inc. where among other roles, he worked to identify and execute upon strategic opportunities for Pfizer's clinical treatments within hospital accounts across the United States. Mr. Shiner holds a B.S. in Business Administration from the University of California, Riverside and an M.B.A from Northern Illinois University.

Mr. Paul stated, "We are pleased to welcome Charlie, a seasoned marketing professional, to Rockwell Medical. This is a pivotal time for our Company as we prepare for the U.S. commercial launch of Dialysate Triferic in the first half of 2019, and we are fortunate to have someone of Charlie's caliber now on board leading our marketing efforts. Charlie has a deep understanding of the renal space and the expertise needed to develop an effective marketing plan that will enable Rockwell Medical to realize the full value of Triferic, as well as, reach physicians and patients across the U.S."

Mr. Shiner said, "Given my marketing experience in the renal industry, I was drawn to Rockwell Medical, because of the significant potential of Dialysate Triferic and IV Triferic to positively impact patients in the dialysis community and global anemia market. I am energized by the opportunity to work alongside Stuart and the team to realize the full potential of the Company's products."